You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

96 Items
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Dec 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Dec 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Paclitaxel - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Paclitaxel - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Dec 2019
Cancer Type: Gynecologic, Germ Cell     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Testis     
Intent: Curative
May 2019
Cancer Type: Genitourinary, Bladder / Urothelial     
Intent: Adjuvant, Palliative
Jun 2019
Cancer Type: Genitourinary, Testis     
Intent: Palliative
Jan 2018
Cancer Type: Gynecologic, Ovary     
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Paclitaxel in Combination with Platinum - First Line - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
New Drug Funding Program
    Paclitaxel in Combination with Platinum - Recurrent - Advanced Ovarian Fallopian Tube or Primary Peritoneal Carcinoma
Aug 2017
Cancer Type: Gynecologic, Cervix     
Intent: Palliative
Apr 2016
Cancer Type: Gynecologic, Endometrial     
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Paclitaxel - First Line - Uterine Papillary Serous Carcinoma (UPSC)
New Drug Funding Program
    Paclitaxel - Recurrent - Uterine Papillary Serous Carcinoma (UPSC)
Oct 2017